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Abstract
Background: Several approaches to medication optimisation by identifying drug-related problems in older people
have been described. Although some interventions have shown reductions in drug-related problems (DRPs),
evidence supporting the effectiveness of medication reviews on clinical and economic outcomes is lacking.
Application of the STOPP/START (version 2) explicit screening tool for inappropriate prescribing has decreased
inappropriate prescribing and significantly reduced adverse drug reactions (ADRs) and associated healthcare costs
in older patients with multi-morbidity and polypharmacy. Therefore, application of STOPP/START criteria during a
medication review is likely to be beneficial.
Incorporation of explicit screening tools into clinical decision support systems (CDSS) has gained traction as a
means to improve both quality and efficiency in the rather time-consuming medication review process. Although
CDSS can generate more potential inappropriate medication recommendations, some of these have been shown
to be less clinically relevant, resulting in alert fatigue. Moreover, explicit tools such as STOPP/START do not cover all
relevant DRPs on an individual patient level. The OPERAM study aims to assess the impact of a structured drug
review on the quality of pharmacotherapy in older people with multi-morbidity and polypharmacy. The aim of this
paper is to describe the structured, multi-component intervention of the OPERAM trial and compare it with the
approach in the comparator arm.
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Method: This paper describes a multi-component intervention, integrating interventions that have demonstrated
effectiveness in defining DRPs. The intervention involves a structured history-taking of medication (SHiM), a
medication review according to the systemic tool to reduce inappropriate prescribing (STRIP) method, assisted by a
clinical decision support system (STRIP Assistant, STRIPA) with integrated STOPP/START criteria (version 2), followed
by shared decision-making with both patient and attending physician. The developed method integrates patient
input, patient data, involvement from other healthcare professionals and CDSS-assistance into one structured
intervention.
Discussion: The clinical and economical effectiveness of this experimental intervention will be evaluated in a
cohort of hospitalised, older patients with multi-morbidity and polypharmacy in the multicentre, randomized
controlled OPERAM trial (OPtimising thERapy to prevent Avoidable hospital admissions in the Multi-morbid elderly),
which will be completed in the last quarter of 2019.
Trial registration: Universal Trial Number: U1111-1181-9400 Clinicaltrials.gov: NCT02986425, Registered 08
December 2016.
FOPH (Swiss national portal): SNCTP000002183. Netherlands Trial Register: NTR6012 (07-10-2016).
Keywords: Geriatric patient, Cluster randomised controlled trial, STOPP/START, Inappropriate prescribing
Contributions to the literature
 Explicit prescribing appropriateness criteria such as
STOPP/START reduce adverse drug reactions and
medication costs in older persons yet
implementation in healthcare systems globally is
low.
 STRIP is a robust system that has been successfully
implemented in Belgium, Ireland, the Netherlands,
and Switzerland as part of the OPERAM trial and
could be integrated in any healthcare system.
Background
The global population aged over 65 years is rapidly in-
creasing such that by 2060 approximately one-third of the
European population is projected to be over 65 years [1].
In this ageing population, there is a higher prevalence of
multi-morbidity, which is in turn associated with greater
mortality [2], decreased quality of life (QoL) and increased
number of hospital admissions [3]. Moreover, these pa-
tients are frequently exposed to multiple medications in
the context of their multi-morbidity i.e. multiple chronic
diseases usually engender multiple prescriptions, also
known as polypharmacy. Although polypharmacy has sev-
eral definitions, the most broadly accepted is that of the
concurrent use of ≥5 medications [4]. Polypharmacy in
older patients has been repeatedly shown to result in
negative consequences such as increased healthcare costs,
adverse drug reactions (ADRs), adverse drug-drug interac-
tions (DDI) and drug-related hospital admissions [5–7].
Importantly, the risk of either ADR or DDI occurrence in-
creases with the number of medications prescribed [8, 9].
Despite this, a recent study demonstrated that across spe-
cific European countries, the issue of problematic poly-
pharmacy has not been widely addressed [10].
Several different approaches to optimise prescription
medication in older people have been reported [11, 12]. In
spite of a general lack of evidence for their significant im-
pact on health-related outcomes, a Cochrane review did
find that one particular approach was beneficial in redu-
cing inappropriate polypharmacy [13], i.e. the novel
geriatric-specific inappropriate prescribing criteria called
Screening Tool of Older Persons’ Prescriptions (STOPP)
and Screening Tool to Alert to Right Treatment (START)
[14]. The first of a series of 5 randomised controlled trials
(RCTs) using the STOPP/START criteria as an interven-
tion demonstrated that the use of these criteria signifi-
cantly improved prescribing appropriateness up to 6
months after discharge in a cohort of older, hospitalised
patients [9]. Further refinements to the criteria resulted in
the publication of STOPP/START version 2 [15] and sub-
sequent studies have shown that application of STOPP/
START criteria can reduce both the incidence of ADRs
and medication costs in older, hospitalised patients [16,
17]. Application of the STOPP/START version 2 criteria
into a structured medication review process is defined as
the Systematic Tool to Reduce Inappropriate Prescribing
(STRIP) [18].
More recently, the European Commission and Swiss
Government-funded OPERAM (OPtimising thERapy to
prevent Avoidable hospital admissions in the Multi-
morbid elderly) project was established based on the use
of the STRIP medication review. The STRIP process en-
compasses the use of a customised software-based tool
known as the STRIP Assistant (STRIPA), which was de-
veloped to support healthcare professionals to perform
the STRIP medication review process. The STRIPA
process then generates a report with prescribing recom-
mendations addressing potentially inappropriate prescrib-
ing (PIP) or potential prescribing omissions (PPOs) [19].
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STRIPA consists of four main components, i.e. functional
architecture, user interface, decision rule engine, and se-
mantic interoperability [20]. For the purpose of the multi-
centre OPERAM trial, the STRIPA software was trans-
lated into four languages; English, German, French and
Dutch.
Integration of STOPP/START criteria into a stand-
alone web-based clinical decision support system (CDSS)
could improve the detection of inappropriate prescrib-
ing. A recent review has demonstrated that compu-
terised interventions can significantly decrease PIP in
hospitalised older adults, although the authors highlight
that larger scale multinational RCTs are needed to sup-
port this contention [21]. Interestingly, other studies that
investigated the benefits of medication review software
based on clinical tools such as STOPP/START confirm
the high identification rate of PIP, but address the fact
that this can result in less clinically relevant recommen-
dations being made [22]. Furthermore, it has been
shown that the majority of DRPs identified during medi-
cation review may not be associated with the STOPP/
START criteria [23]. Taken together, these results sug-
gest that the application of STOPP/START alone does
not adequately detect all drug-related errors and that
consequently a more complex intervention is necessary
to optimise the medication review process. Therefore, a
structured assessment, including a patient interview that
identifies health and medication issues, combined with a
medication review facilitated by a CDSS and evaluated
by trained healthcare professionals, could potentially
identify the most relevant drug-related problems.
The aim of the OPERAM study is to assess the im-
pact of a structured drug review utilising the STRIP
method, including STRIPA software, on the quality of
Fig. 1 Flowchart of STRIP and STRIPA intervention process. Abbreviations: STRIPA = Systematic Tool to Reduce Inappropriate Prescribing Assistant;
SDM = shared decision making; IP = internal physician; ICD-10 = International Statistical Classification of Disease and related Health Problems, 10th
revision; ATC = Anatomical Therapeutic Chemical; LOINC = Logical Observation Identifiers Names and Codes; SHiM = structured history-taking of
medication; GP = general practitioner
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pharmacotherapy and whether such optimisation of
pharmacotherapy in older people can reduce the num-
ber of drug-related hospital admissions in older patients
with multi-morbidity and polypharmacy hospitalised
previously (i.e. at enrolment into OPERAM) [24].. The
trial protocol has been described elsewhere [25]; the
aim of this report is to describe the structured, multi-
component intervention and compare it with the ap-
proach in the comparator arm (see Fig. 1. Flowchart of
STRIP and STRIPA intervention process). This proto-
col has been written in line with Standard Protocol
Items: Recommendations for Interventional Trials
(SPIRIT) recommendations (see Additional File 1).
Methods/design
Intervention arm
The STRIP intervention as in OPERAM
Step 1: Structured History-taking of Medication (SHiM)
In order to optimise patients’ pharmacotherapy during
their hospital stay, their medication lists have to be as ac-
curate as possible at the point of arrival. Several studies
have shown that older patients’ medication lists on admis-
sion to hospital significantly differ from what they actually
take at home [26–29]. These differences can be of clinical
significance, causing adverse drug events (ADEs) or pa-
tient harm [30, 31] and older patients are particularly at
risk from these events [32]. Medicines reconciliation as an
intervention has repeatedly been shown to reduce medica-
tion discrepancies and to improve the accuracy of medica-
tion lists [26, 29], although there is no clear consensus on
the most accurate method of carrying out medicines’ rec-
onciliation. Different sources for obtaining information on
medication history include letters from referring physi-
cians, community pharmacy dispensing lists and patients’
own medications, although none of these methods is com-
pletely accurate when taken in isolation and the use of
several sources is recommended [31]. To address this
problem, the Structured History-taking of Medication
(SHiM) was devised by Spee and colleagues [33] who de-
veloped a 21-item questionnaire that can be used to fully
interrogate a patient’s current medication use (including
non-prescription medications), patient’s attitudes and be-
liefs towards their own medication regime, any perceived
barriers to medication use as well as any known medica-
tion allergies or intolerances [28]. Application of the
SHiM has been shown to successfully detect discrepancies
in medication lists in up to 92% of patients being admitted
to hospital, reducing potential patient harm as a result of
addressing these errors [28, 34].
In OPERAM, a SHiM assessment is conducted for all
intervention patients, either with the patients themselves
or their next-of-kin in the case of patients with cognitive
impairment, typically between 24 and 72 h after inclu-
sion in the trial. It is completed by a trained researcher
(pharmacist, physician or nurse) and is performed separ-
ately to the routine clinical history-taking which is com-
pleted on admission by a member of the attending
medical team. In OPERAM, a modified version of the
SHiM is used, which has removed the final 7 questions
from previously described versions [28] (see Table 1.
Questions in the modified SHiM used in the OPERAM
trial). In addition to the SHiM, at least one other source
is consulted. Preferably, a complete medication dispens-
ing list is obtained from the community pharmacy and/
or the general practitioner (GP), or if not available, a list
of medications on admission is taken from the patient’s
medical records or from the primary care physician’s re-
ferral letter.
Step 2: Clinical Decision Support System with integrated
STOPP/START (STRIPA)
The pharmaceutical analysis within the OPERAM trial
is carried out by a trained research physician and a
trained research pharmacist in mutually supportive roles
assisted by the STRIPA software. STOPP/START cri-
teria (version 2) were converted into clinical rules
though an extensive, multi-disciplinary process, and
these rules were then incorporated into the stand-alone
CDSS to assist clinicians in detection of PIP and PPOs.
However, suggestions can also be manually entered
based on expert opinion by the trained research phys-
ician or pharmacist. Within STRIPA, the patient demo-
graphic data are entered anonymously, and baseline data
including details of age, gender and race are recorded.
Table 1 Questions in the modified SHiM used in the OPERAM
trial
Questions on individual drug level
1. Are you using this drug as prescribed? (dosage, dose frequency and
dosage form)
2. If not, what is the reason for deviating (from dosage, frequency or
form) or not taking the drug at all?
3. Are you experiencing any side-effects from taking this drug?
Questions on a general level
4. Are you using any other prescription drugs that are not mentioned
on this list?
5. Are you using non-prescription drugs?
6. Are you using homeopathic drugs or herbal medicines?
7. Are you using drugs that belong to family members or friends?
8. Are you using any ‘as needed’ drugs?
9. Are you using drugs that are no longer prescribed?
10. Do you have any drug allergies?
11. Do you have any drug intolerances?
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Race is entered as either black or non-black for the sole
purpose of calculating the estimated Glomerular Filtra-
tion Rate (eGFR) using the Chronic Kidney Disease Epi-
demiology Collaboration (CKD-EPI) formula [35, 36].
The patient clinical data are then entered as medical
conditions using the International Statistical Classifica-
tion of Disease and related Health Problems, 10th revi-
sion (ICD-10) codes, current medications as Anatomical
Therapeutic Chemical (ATC; level 5) codes and mea-
surements such as blood pressure, bone mineral density
and laboratory values using Logical Observation Identi-
fiers Names and Codes (LOINC) codes. The different
steps taken during data entry and analysis will now be
described in greater detail.
Data entry
After entering the baseline patient characteristics, the
patient’s medical data are entered in five sequential
steps:
(1) All relevant medical conditions (either chronic or
acute) are entered using ICD-10 codes. Surgical in-
terventions not requiring (current) medical treat-
ment are not considered for data input. Coronary
artery stent deployment, for example, is entered as
this treatment requires antiplatelet therapy for 6–
12months. For some medical conditions, the date
of onset is important and this can also be entered
during this step.
(2) All current medications are entered (including
those upon admission) at ATC-5 level (generic drug
names), including frequency and route of adminis-
tration. This may differ from the patient’s home
medication. Additionally, drugs with a long-term in-
dication that have been withheld upon admission
due to the specific nature of the patient’s presenting
illness are included, as their re-initiation after
hospitalization is likely.
(3) All patient-reported signs and symptoms are en-
tered. They are either elicited from the patient dur-
ing SHiM or found in the medical records or in the
laboratory results. A predefined list of signs and
symptoms present in START and STOPP criteria in
the form of checkboxes is available in STRIPA, and
includes for example constipation, dizziness, blurred
vision and ankle oedema, among others. Other signs
or symptoms can be entered manually and then se-
lected from the Medical Dictionary for Regulatory
Activities (MedDRA) database, a medical dictionary
developed by the International Council for
Harmonization of Technical Requirements for
Pharmaceuticals for Human Use (ICH), integrated
with STRIPA.
(4) All available vital and laboratory measurements are
reviewed. However, only those parameters present
within one or more of the STOPP and START
criteria are available within STRIPA. These can
either be entered manually or selected from the
predefined list of parameters present.
(5) The final step in the data entry process comprises
different measurements, specifically the HAS-BLED
score [37], clinical parameters such as urea and
electrolyte values, heart rate and blood pressure, pa-
tient height and weight as well as the pneumococcal
and influenza vaccination status. Additionally, aller-
gies and ADRs can be entered here as plain text.
STRIPA analysis
The pharmaceutical analysis consists of six steps, ac-
cording to the Prescribing Optimization Method [38], at
the end of which a report with prescribing recommenda-
tions is generated. These steps are as follows:
1. Assignment of medication to the recorded
diagnoses: the STRIPA user assigns all the entered
medications to the present ICD-10 codes represent-
ing the patient’s medical conditions (see Fig. 2.
Screenshot of STRIPA process during which medi-
cations are assigned to relevant medical conditions).
This can be achieved by ‘dragging’ the medications
by screen cursor on the ‘right side’ of the screen to
the corresponding indicated medical condition on
the ‘left side’ of the screen. Where no appropriate
indication for a medication is present, this medica-
tion can be assigned to ICD-10 code ‘R69- unknown
and unspecified causes of morbidity’, i.e. a so-called
‘dummy condition’.
2. Screening for under-treatment: during this step, the
entered medications and medical conditions are
checked for under-treatment according to START
criteria (see Fig. 3. A screenshot of triggered
START criteria). All medications assigned to a med-
ical condition are evaluated, regardless of the spe-
cific medical condition they were assigned to. For
instance, where an ACE inhibitor is assigned to
hypertension instead of heart failure, START rule
A6 (“Angiotensin Converting Enzyme (ACE) inhibi-
tor with systolic heart failure and/or documented
coronary artery disease”) will not be triggered as the
ACE inhibitor is already present in the medication
list. The intervention team will evaluate all gener-
ated START rules on their appropriateness for a
specific patient by either accepting or rejecting the
advice. In the event of a rejected recommendation,
the reasons for rejection are not recorded within
the STRIPA software. When a START recommen-
dation is accepted, the user can choose any
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medication on an ATC-5 level, including preferred
dose, within the advised class from a drop-down
menu. This drug is then automatically assigned to
the medical condition triggering the rule. When
more than one criterion is triggered advising the
same drug (or drug class), the best matching criter-
ion is chosen by the intervention team and the
others are then automatically disabled. At the end
of this step, the updated medication list is evaluated
for potential under-treatment not highlighted in
START criteria, but considered relevant according
to the STRIPA software user. In such cases, these
drugs can be manually added to the designated
medical condition and will appear on the final ad-
vice report as ‘expert opinion’ instead of triggered
by START criteria.
3. Screening for over-treatment: this step involves
evaluation of over-treatment according to STOPP
criteria. All medications including those initiated in
the prior step are evaluated based on the medical
conditions and known biomedical parameters and
symptoms or complaints. During this step, the
newly initiated medications, including START
criteria-based recommendations accepted during
the previous step, could also appear as STOPP rec-
ommendations. For example, in the previous step
an ACE inhibitor was started according to START
rule A6. However, due to the presence of hyperka-
laemia, STOPP rule B11 (“ACE Inhibitors or Angio-
tensin Receptor Blockers in patients with
hyperkalaemia”) would then be triggered. The user
decides whether these STOPP recommendations
are relevant to the patient under review. If a recom-
mendation is followed, the medication in question
will then be removed from the recommended medi-
cations list. They will appear on the final report as
‘medication advised to be stopped’. All medications
that could not be assigned to an appropriate med-
ical condition and have therefore been allocated the
ICD-10 code ‘R69’ are considered potential over-
treatment. Moreover, the STOPP criteria addressing
impaired renal function and combinations with cer-
tain medications (e.g. digoxin and eGFR < 30 ml/
min) will be triggered here, based on either entered
Fig. 2 Screenshot of STRIPA process during which medications are assigned to relevant medical conditions
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eGFR values or an ICD-10 diagnosis of renal insuffi-
ciency. In addition to stopping medications, the
user could also decide to recommend a dose adjust-
ment (both manually and based on STOPP criteria).
4. Medication-Disease Interactions (ADEs): this step
encompasses the adjudication of clinical signs or
symptoms entered which are based on the
predefined list of symptoms and signs that may be
attributable to medications or medical conditions.
The software user, based on expert opinion, can
assign symptoms and signs manually to medications
and a drop-down menu with three possible actions
appears: (A) The symptom/sign can be registered as
‘side effect’ of the concerning medication; (B) The
medication can be either maintained, stopped or ad-
justed; (C) Adaptations to other drugs can be made
including stopping, adjusting or starting new drugs.
All assigned symptoms and signs will appear on the
report linked to their possible causative medication.
5. Medication-Medication Interactions: during the
fifth step, the medication list will be checked for
drug-drug interactions based upon the incorporated
or local interaction database (dependent on licens-
ing) within the software. If an interaction is identi-
fied, the user can again choose to act upon or
ignore the prompt. An explanation about the inter-
action is present to assist the software user in this
decision process. When a drug-drug interaction is
addressed, the software user must decide which
medication to maintain, stop or adjust. Also, other
drugs from the medication list can be adapted here
and a new medication can be initiated, for instance
to replace one of the interacting medications.
6. Dosage: the final step consists of dose adjustment
recommendations based on the Dutch KNMP
Kennisbank® database and the patient’s calculated
eGFR. When a recommendation is acted upon, the
software user can choose to maintain, stop or adjust
the concerned medication and/or take other actions
including adjustment of other medications in the
list or starting a new medication.
After completing the steps above, the analysis is final-
ized. All choices made are then saved within the STRIPA
Fig. 3 A screenshot of triggered START criteria
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system and tracked in the background. However, the dif-
ferent steps of the analysis can be revisited at all times, if
necessary. When the analysis is considered complete, an
overview of all the adaptations to the medication list can
be viewed in the ‘advice tab’. Here, all suggested medica-
tions to be discontinued are shown in red, newly started
medications are in green and manually adjusted medica-
tions appear in italics. The medications are still linked to
the corresponding medical condition and will appear cor-
respondingly on the report. In the advice tab, the user can
manually adapt the plain text of both medical conditions
and medications to enhance the final report presented to
the patient’s prescribing (internal) physician (see Fig. 4a.
The internal physician report: (A) final screen in the
STRIPA process, and (B) completed report). This will not
affect the underlying ATC and ICD-10 codes saved in the
STRIPA track. Furthermore, comments on the recom-
mendations (other than explanations of STOPP and
START criteria which will appear on the report regard-
less) can be added by the user according to each proposed
medication change in order to convince the prescribing
physician to follow the advice or to emphasize the import-
ance of the recommendation. Moreover, recommenda-
tions can be deferred to the patient’s primary care
physician when they are not deemed appropriate to the
current acute clinical situation. Lastly, a general comment
box exists where the software users can enter extra infor-
mation or considerations regarding the recommendation
or general points of attention relevant to this patient. After
all adaptations are made, the report known as the ‘internal
physician report’ (see Fig. 4b. The internal physician re-
port: (A) final screen in the STRIPA process, and (B) com-
pleted report) can be downloaded and printed for
discussion with the prescribing hospital physician.
Step 3: Communication and discussion of the STRIPA
report with the prescribing physician
After the first analysis has been conducted and the
prescribing physician report is complete, the research
pharmacist and research physician contact the prescrib-
ing physician and discuss the implementation of the
STRIPA-generated recommendations. The objective is
to incorporate the prescribing recommendations with
the insight that the prescribing physician can provide
with regards to the overall functional capacity of the pa-
tient to reach a consensus about the recommendations
that should be implemented to prevent both ADRs dur-
ing the hospital stay, and later drug-related readmissions
(i.e. the primary endpoint of the OPERAM trial).
Step 4. Shared-decision making with the patient
Subsequently, once consensus has been reached be-
tween the researchers and the prescribing physician, the
process of shared decision-making (SDM) can take place
if the prescribing physician has identified preference-
sensitive decisions with regard to stopping, starting, con-
tinuing or selecting medications for discussion with the
patient. SDM has been defined as “an approach where
Fig. 4 The internal physician report: (a) final screen in the STRIPA process, and (b) completed report
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healthcare professionals and patients share the best avail-
able evidence when faced with making decisions regarding
healthcare, and where patients are supported to consider
options to achieve informed preferences” [39]. This process
addresses patients’ autonomy and promotes patient en-
gagement [39], and it has repeatedly been shown to play
an integral role in a successful de-prescribing of harmful
drugs [40–42].
The model for SDM has previously been described
elsewhere [43]. Briefly, it is centred around 4 main prin-
ciples i.e. ‘choice talk’, ‘option talk’, ‘preference talk’ and
‘decision talk’ [43]. All patients, in particular patients
with cognitive impairment, should be facilitated to have
another relevant person (e.g. close family member)
present when making any decisions in the SDM process.
Collectively, the research team and the patient agree on
definitive medication changes to be made and then
proceed to develop a pharmaceutical care plan. Changes
after the SDM process are communicated to the pre-
scribing physician, and in some cases, the SDM can be
deferred to the patient’s GP; if so, this is documented on
the GP information letter, as will be discussed in the
next section.
Step 5: Discharge and the GP information report
Once recommendations are agreed between the re-
search team, the prescribing physician and the patient,
the changes to the patient’s medications are entered into
STRIPA and a report known as the “GP report” is gener-
ated. Where the prescribing physician has accepted
STRIPA recommendations, these recommendations are
included in the GP report. Where the prescribing phys-
ician has made changes unrelated to STRIPA, these
changes are entered manually. In cases where SDM is
deferred to the GP, instructions for the GP are written
by either the research physician or research pharmacist
in the section of the GP report entitled “recommenda-
tions not yet applied during hospitalization”. The GP re-
port should then be identical to the patient’s discharge
prescription, and is mailed to the GP after the patient is
discharged from hospital.
Control arm and SHAM intervention
Patients in the control group receive usual care, with the
potential of a medication review by the prescribing phys-
ician in accordance with usual pharmaceutical care. Pa-
tients from both groups complete the 8-item Moriskey
Medication Adherence Scale questionnaire (MMAS-8)
[44] with a trained member of the intervention team.
This is to prevent potential unblinding in the event of
unblinded team members approaching patients when at-
tending patients’ wards.
Device deficiency
Due to a software tool being used in this trial, there is
the potential for a so-called device deficiency, defined by
the European Medical Device Vigilance System (MED-
DEV) 2.7/3 [45] as an “Inadequacy of a medical device
related to its identity, quality, durability, reliability,
safety or performance. This may include malfunctions,
use error, or inadequacy in the information supplied by
the manufacture.” All technical problems with the
STRIPA system are reported, using the designated
STRIPA feedback form, within 24 h to the software de-
velopers, who then assess whether the problem in ques-
tion is a possible device deficiency. They will then report
back within 72 h to the clinical site in question with de-
tails of the investigation of the issue and determine any
actions to be taken. If corrective actions are required at
all sites, all co-Principal Investigators (PIs) including the
co-ordinating PI are informed within another 48 h.
Safety section
The STRIPA software provides general recommenda-
tions and is not intended to impose firm decisions. It
does not replace decision-making and clinical judge-
ments made by physicians and pharmacists and this is
explicitly stated in the disclaimer on the printed reports.
It is expected that prescription recommendations made
by the STRIPA system that turn out to be inappropriate
for an individual patient are detected by a pharmacist or
physician conducting the intervention and addressed ap-
propriately to safeguard patients’ welfare. The prescrib-
ing physicians remain responsible for all final medical
decisions concerning their patients.
Discussion
ADRs, which are particularly likely to occur during acute
hospital admission, cause significant morbidity in older
patients and contribute to increased healthcare costs [45].
ADRs are common in older multi-morbid patients and
often lead to acute hospitalization despite reports that ap-
proximately 50% of these drug-related admissions (DRA)
are likely to be preventable [7, 46]. Growing evidence indi-
cates that optimising pharmacotherapy, through various
interventional designs, mitigates inappropriate prescribing
as well as the incidence of ADRs and associated costs in
this high-risk patient population [11, 15, 16]. Although
there is insufficient data to support the use of a single vali-
dated intervention, a recent review highlighted the value
of several methods including close liaison between physi-
cians and clinical pharmacists as well as the use of implicit
and explicit prescribing criteria such as STOPP/START
[11]. A particular strength of the OPERAM trial is its nov-
elty, i.e. it is one of the first computerised interventions
designed to incorporate a structured medication review to
look at potentially inappropriate prescribing and potential
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prescribing omissions in older hospitalised patients, and
assesses whether it reduces drug-related hospital admis-
sions. It also recognises the importance of the identifica-
tion of patient-reported clinical signs and symptoms that
may be related to PIP. Moreover, it relies on multi-
disciplinary input and collaboration between physicians
and pharmacists and clear communication of prescribing
information with GPs, which will likely increase the im-
pact of prescribing recommendations on patient care. Fi-
nally, the SDM process allows for greater emphasis to be
placed on a patient-centred approach, encouraging patient
engagement with their own healthcare. The integration of
multiple interventions that have demonstrated benefit is
anticipated to have a synergistic effect on pharmacother-
apy quality. The study can also demonstrate the feasibility
of a multi-component intervention in a hospital environ-
ment. A key strength of the OPERAM trial will be its
demonstration of feasibility in differing healthcare envi-
ronments of the EU and non-EU countries. The OPERAM
trial will also analyze the intervention from a health eco-
nomics perspective and will allow for the determination of
the benefit that the intervention can provide to society in
general through a reduction in healthcare expenditure. Re-
cruitment for the OPERAM trial began in December 2016
and finished in October 2018. Trial follow-up will be com-
pleted in October 2019 and trial results are expected in
the first quarter of 2020.
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